

NEWSLETTER November–December 2019

CEO's greetings

What an amazing end for the year 2019. Who says drug development is slow and nothing ever happens? In just December we have:

- Completed a share issue, which was oversubscribed multiple times
- Listed our shares in First North Stockholm
- Completed patient recruitment in our Phase 2 study AdeLE in secondary lymphedema
- Had the last patient visit in the main part of our Phase 1-2 study in Parkinson's disease
- Selected the lead candidates for xCDNF
- Presented our Lymfactin® poster at the main global Breast Cancer event, San Antonio Breast Cancer Symposium in Texas, USA

I won't promise this much results in every newsletter. But we certainly look forward to an exciting year. Our very best wishes for your New Year 2020!

CLINICAL STUDIES

- **Parkinson's disease:** Phase 1–2 study with CDNF: Main study completed; Extension study continues. First results are expected in Q1/20.
- **Breast Cancer Associated Lymphedema:** Phase 2 study AdeLE is fully recruited. Results are expected in Q1/21 after a 12-month blinded follow-up. See [Lymfactin website](#) for details.
- **Breast Cancer Associated Lymphedema:** Phase 1 study is in long-term follow-up. Based on 12-month follow-up, Lymfactin® is safe and well tolerated.

PLANNED ACTIVITIES

- **JP Morgan Healthcare Conference**, 13-16 Jan 2020 in San Francisco: Meetings with potential partners, investors, and other healthcare professionals
- **Swiss Nordic BIO 2020**, 6 Feb 2020: International investor and partnering event in Zurich, Switzerland
- **Financial statements release for 2019**, 27 Feb 2020
- **Annual Report for 2019**, 17 Mar 2020
- **ABGSC Investor Days at Haymarket**, 18-19 Mar 2020 in Stockholm: Company presentation to Swedish investors
- **Annual General Meeting**, 8 Apr 2020 in Helsinki

Herantis of the month



Nasdaq's little helpers! Herantis' management and board members in bell ringing ceremony in Stockholm

Keep up-to-date on Herantis:



Highlights from team

Bell-ringing ceremony at Nasdaq Stockholm, to celebrate the launch of trading of our shares in Stockholm with ticker \$HRNTS! Trading under \$HRTIS continues in Helsinki.

Outi presented our Lymfactin® poster at the San Antonio Breast Cancer Symposium in Texas, USA. It was received well with a lot of interest: The breast cancer community is aware of the significant need for efficacious treatments for lymphedema.

Topics of interest

Patient-focused drug development is a topic close to our hearts and also emphasized by the FDA in their [Guidance Series](#). This is exactly what we plan to do when preparing for our Phase 3 study in lymphedema.

Published data shows CDNF-lacking mice have an altered dopamine function in brain and degeneration of enteric neurons. This is very interesting in the context of common symptoms of Parkinson's disease.

Herantis in the news

Herantis mentioned several times in the Swedish investor podcast Placerapodden in episode "[Aktien är en potentiell tenbagger](#)" ("The share is a potential tenbagger").

An article in a Finnish Parkinson's association's magazine discusses the potential of CDNF and the general challenges in drug development in Parkinson's (in Finnish).

Herantis' CEO Pekka Simula interviewed by [News Agency Direkt](#).